The KEYNOTE-177 trial showed that front-line therapy with pembrolizumab resulted in a significant increase in progression-free survival (PFS) in patients with MSI-H dMMR metastatic colorectal cancer compared to chemotherapy. The study involved 307 patients randomly assigned to receive either pembrolizumab or standard-of-care chemotherapy, with pembrolizumab demonstrating a median PFS of 16.5 months compared to 8.2 months with chemotherapy. Pembrolizumab also showed a higher response rate and more durable responses, with fewer adverse events compared to chemotherapy. The study suggests pembrolizumab as a potential first-line treatment option for MSI-H mCRC patients, especially for those with specific criteria.
Source link
Paradigm-Changing Study Results for MSI-H Metastatic CRC
